World's Best Scientists 2026 revealed!
Kevan C. Herold

Kevan C. Herold

D-Index & Metrics

Immunology

D-Index
99
Citations
36621
World Ranking
749
National Ranking
425

Medicine

D-Index
99
Citations
37046
World Ranking
8578
National Ranking
4419

Kevan C. Herold publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Kevan C. Herold sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 356 publications — 75th percentile

75% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Kevan C. Herold D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Kevan C. Herold sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 99 D-Index — 85th percentile

85% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Kevan C. Herold is affiliated with Yale University in the United States and has contributed extensively to academic research in medicine and biochemistry, genetics, and molecular biology. Their work spans various subfields, including genetics, endocrinology, diabetes and metabolism, surgery, immunology, and oncology.

Their research interests focus primarily on diabetes and associated disorders, diabetes management and research, pancreatic function and diabetes, immune cell function and interaction, cancer immunotherapy and biomarkers, diabetes treatment and management, and COVID-19 clinical research studies.

Herold has published numerous papers in several reputed scientific venues, with frequent contributions to journals such as Diabetes, Diabetes Care, The Journal of Immunology, Journal for ImmunoTherapy of Cancer, and bioRxiv (Cold Spring Harbor Laboratory).

Notable recent papers include:

  • Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients (2020, Science Translational Medicine)
  • Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals (2021, Science Translational Medicine)
  • Quantifying the effect of experimental perturbations at single-cell resolution (2021, Nature Biotechnology)
  • The effect of low-dose IL-2 and Treg adoptive cell therapy in patients with type 1 diabetes (2021, JCI Insight)
  • Immunotherapy: Building a bridge to a cure for type 1 diabetes (2021, Science)

Frequent co-authors collaborating with Herold include:

  • Jay M. Sosenko
  • María J. Redondo
  • Emily K. Sims
  • Heba M. Ismail
  • Stephen E. Gitelman

Herold's body of work demonstrates a strong focus on diabetes-related research, evidenced by a high number of publications specifically in diabetes-focused journals. Their contributions to immunology and oncology also integrate with their medical research pursuits.

Best Publications

  • Genetics, pathogenesis and clinical interventions in type 1 diabetes

    Jeffrey A. Bluestone;Kevan Herold;George Eisenbarth

  • Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus

    Kevan C. Herold;William Hagopian;Julie A. Auger;Ena Poumian-Ruiz

  • Staging Presymptomatic Type 1 Diabetes: A Scientific Statement of JDRF, the Endocrine Society, and the American Diabetes Association.

    Richard A. Insel;Jessica L. Dunne;Mark A. Atkinson;Jane L. Chiang

  • Type 1 diabetes immunotherapy using polyclonal regulatory T cells.

    Jeffrey A. Bluestone;Jane H. Buckner;Mark Fitch;Stephen E. Gitelman

  • Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation

    Ravichandran Ramasamy;Susan J. Vannucci;Shirley Shi Du Yan;Kevan Herold

  • An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes

    Kevan C. Herold;Brian N. Bundy;S. Alice Long;Jeffrey A. Bluestone

  • Differential effects of anti-B7-1 and anti-B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse.

    Deborah J. Lenschow;Stephen C. Ho;I Husain Sattar;Lesley Rhee

  • A Single Course of Anti-CD3 Monoclonal Antibody hOKT3γ1(Ala-Ala) Results in Improvement in C-Peptide Responses and Clinical Parameters for at Least 2 Years after Onset of Type 1 Diabetes

    Kevan C. Herold;Stephen E. Gitelman;Umesh Masharani;William Hagopian

  • Reprogramming human T cell function and specificity with non-viral genome targeting

    Theodore L. Roth;Cristina Puig-Saus;Ruby Yu;Ruby Yu;Eric Shifrut;Eric Shifrut

  • Familial Hyperinsulinism Caused by an Activating Glucokinase Mutation

    B Glaser;P Kesavan;M Heyman;E Davis

  • C-Peptide Is the Appropriate Outcome Measure for Type 1 Diabetes Clinical Trials to Preserve β-Cell Function: Report of an ADA Workshop, 21–22 October 2001

    Jerry P. Palmer;G. Alexander Fleming;Carla J. Greenbaum;Kevan C. Herold

  • Control of TH17 cells occurs in the small intestine.

    Enric Esplugues;Enric Esplugues;Enric Esplugues;Samuel Huber;Samuel Huber;Nicola Gagliani;Anja E. Hauser

  • Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors

    Angeliki M. Stamatouli;Zoe Quandt;Ana Luisa Perdigoto;Pamela L. Clark

  • Teplizumab for treatment of type 1 diabetes (Protege study): 1-year results from a randomised, placebo-controlled trial.

    Nicole Sherry;William Hagopian;Johnny Ludvigsson;Sunil M Jain

  • Teplizumab (Anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders

    Kevan C. Herold;Stephen E. Gitelman;Mario R. Ehlers;Peter A. Gottlieb

  • CD28/B7 Regulation of Th1 and Th2 Subsets in the Development of Autoimmune Diabetes

    Deborah J. Lenschow;Kevan C. Herold;Lesley Rhee;Bina Patel

  • TCR stimulation with modified anti-CD3 mAb expands CD8+ T cell population and induces CD8+CD25+ Tregs

    Brygida Bisikirska;John Colgan;Jeremy Luban;Jeffrey A. Bluestone

  • Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial

    Diane K Wherrett;Brian Bundy;Dorothy J Becker;Linda A DiMeglio

  • Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.

    Antoinette Moran;Brian Bundy;Dorothy J. Becker;Linda A. DiMeglio

  • Immune responses to SARS-CoV-2 infection in hospitalized pediatric and adult patients.

    Carl A. Pierce;Paula Preston-Hurlburt;Yile Dai;Clare Burn Aschner

  • TCR stimulation with modified anti-CD3 mAb expands CD8 + T cell population

    Brygida Bisikirska;John Colgan;Jeremy Luban;Jeffrey A. Bluestone

Frequent Co-Authors

Jeffrey A. Bluestone
Jeffrey A. Bluestone University of California, San Francisco
Carla J. Greenbaum
Carla J. Greenbaum Virginia Mason Medical Center
Jerry P. Palmer
Jerry P. Palmer University of Washington
Jay S. Skyler
Jay S. Skyler University of Miami
Mark A. Atkinson
Mark A. Atkinson University of Florida
Jeffrey P. Krischer
Jeffrey P. Krischer University of South Florida
Desmond A. Schatz
Desmond A. Schatz University of Florida
Ann Marie Schmidt
Ann Marie Schmidt New York University
Linda A. DiMeglio
Linda A. DiMeglio Indiana University
Raphael Clynes
Raphael Clynes Columbia University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a career in immunology often intersects with various healthcare disciplines, particularly nursing specialties focused on patient immune response and related conditions. Aspiring professionals can explore accelerated paths, such as an accelerated np program, which offers a fast-tracked approach to becoming a nurse practitioner with specialized knowledge valuable in immunology-related fields.

For those already in nursing, transitioning to acute care is a viable option with programs like an fnp to acnp bridge program online, equipping nurse practitioners with critical skills for managing complex immune system disorders. This flexibility allows for career growth in both clinical and research settings.

Financial considerations are key when selecting education pathways. Some of the cheapest online pmhnp certificate programs offer an affordable entry point, enabling learners to minimize debt while gaining credentials relevant to immunology-related mental health conditions.

Career prospects also depend on specialization. Graduates often target high-demand, well-compensated roles, reminiscent of those found in the highest paid dnp specialties, where expertise in immunology can enhance earning potential and job satisfaction.

Best Scientists Citing Kevan C. Herold

Trending Scientists

Recently Published Articles